Speaker Profile

Chief Financial Officer, AgeX Therapeutics

Biography
Having served as Chief Financial Officer for a variety of both public and private life sciences companies, Russell Skibsted brings over 25 years’ life sciences business experience to AgeX. Prior to joining AgeX, he was CFO of AgeX’s former parent company, BioTime, Inc (now Lineage Therapeutics), which he joined in November 2015. Prior to BioTime he was CFO at Proove Biosciences, a commercial-stage diagnostics and personalized medicine company. Before that he was Senior Vice President, CFO, and Secretary of Aeolus Pharmaceuticals, a biotechnology company that received over $150M in government funding in the biodefense and oncology sectors. Mr. Skibsted also served as SVP and Chief Business Officer of Spectrum Pharmaceuticals, a commercial-stage pharmaceutical company, and CFO of Hana Biosciences. Earlier in his career, Mr. Skibsted was Partner and CFO at Asset Management Company, one of the oldest and most respected venture capital firms in Silicon Valley.


Emerging Therapeutics Showcase:
AgeX Therapeutics, Inc.

AgeX Therapeutics developments novel therapeutics targeting human aging, developing medicines designed to address large unmet medical needs.

 Session Abstract – PMWC 2020 Silicon Valley


The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.